Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Rigel Pharmaceuticals maintains strong sales momentum across its three approved targeted therapies, justifying a continued Buy rating. RIGL trades at a low P/E of ~7 despite robust 2025 revenue growth and positive cash flow, suggesting undervaluation relative to peers. Pipeline risk remains, as R289 for lower-risk MDS is still early-stage and highly speculative, with no imminent label expansions for existing drugs.

Rigel Pharmaceuticals, Inc. (RIGL) Q4 2025 Earnings Call Transcript

Rigel Pharmaceuticals (RIGL) came out with quarterly earnings of $1.14 per share, missing the Zacks Consensus Estimate of $1.33 per share. This compares to earnings of $0.8 per share a year ago.

Fourth quarter 2025 total revenues of approximately $69.8 million, including record net product sales of $65.4 million and contract revenues of $4.4 million 2025 total revenues of approximately $294.3 million, including net product sales of $232.0 million and contract revenues of $62.3 million Generated $268.1 million of net income in the fourth quarter of 2025 and $367.0 million for the full year, which included approximately $245.9 million of non-cash deferred income tax benefit Enrollment in the dose expansion phase of the Phase 1b study evaluating R289 in patients with lower-risk MDS is ongoing and Rigel is on track to complete enrollment and select the recommended Phase 2 dose for future clinical studies in the second half of 2026 2026 Outlook: Rigel anticipates full-year total revenues of approximately $275 to $290 million, including net product sales of $255 to $265 million, and positive net income for the full year Conference call and webcast scheduled today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif.

Rigel (RIGL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will report its fourth quarter and full year 2025 financial results after market close on Tuesday, March 3, 2026.